Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related dead worldwide and accounts for over 85% of all lung cancers. Furthermore, the majority of patients with NSCLC present with advanced, metastatic disease at the time of diagnosis. For most patients with non-small cell lung canc...
Main Authors: | Maddalena Zippi, Angeloluca De Quarto, Chiara Marzano, Claudio Cassieri, Pietro Crispino, Giampiero Traversa, Giuseppe Occhigrossi, Paola Gnerre, David Terracina |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2016-08-01
|
Series: | Italian Journal of Medicine |
Subjects: | |
Online Access: | http://www.italjmed.org/index.php/ijm/article/view/689 |
Similar Items
-
The management of the patient with non-variceal upper gastrointestinal bleeding: from evidence to clinical practice
by: Maddalena Zippi, et al.
Published: (2016-12-01) -
Erlotinib-induced dry eye
by: Rashmita Ravisankar, et al.
Published: (2023-01-01) -
Modified Synthesis of Erlotinib Hydrochloride
by: Leila Barghi, et al.
Published: (2012-06-01) -
Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2023-10-01) -
Erlotinib in Patients with Advanced Non-small Cell Lung Cancer in Middle Eastern Population
by: Abdul Rahman Jazieh, et al.
Published: (2018-07-01)